Drugs / Diphenydramine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00185692 Background | Aug 2000 → Dec 2010 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, cancer, graft versus host disease +1 | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT03368664 Background | Oct 2017 → May 2021 | multiple sclerosis | Genzyme, a Sanofi Company | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphenydramine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00185692 ↗ |
| Route | Intravenous | “50 mg IV, 30 minutes prior to infusion” NCT00185692 ↗ |